
ExpreS²ion appoints new Vice President, Business Development

Hørsholm, Denmark, April 26, 2021 – ExpreS²ion Biotech Holding AB (“ExpreS²ion” or the “Company”) hereby announces that it has appointed Mr. Eske Rygaard-Hjalsted as new Vice President, Business Development. Mr. Rygaard-Hjalsted brings more than 25 years of sales, marketing, and business development experience and will be focused on growing the Company’s commercial foothold, both with respect to the development pipeline activities and the contract research services. Mr. Rygaard-Hjalsted will begin his employment on May 1, 2021 and be based out of ExpreS²ion’s headquarters in Hørsholm, Denmark.

Mr. Rygaard-Hjalsted (55) joins ExpreS²ion with over 25 years of experience in sales, marketing, and business development in the *life sciences* industry. He joins ExpreS²ion from Intomics A/S, where he held the position as Vice President Sales, Marketing and Business Development. He has held previous positions at DAKO/Agilent A/S, Foss Analytical A/S, and other international companies. He has an MSc Molecular Biology degree from the Technical University of Denmark (DTU) from 1991.

ExpreS²ion’s CEO Bent Frandsen comments:

“It is with great pleasure that Eske is joining ExpreS²ion to support our commercial activities. I trust his experience will ensure a wider outreach in our business development efforts.”

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmq.se

For further information about ExpreS²ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS²ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.